Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.86 |
| ▸ | LMNA | P02545 | 6/20 | 0.86 |
| ▸ | MEN1 | O00255 | 5/20 | 0.86 |
| ▸ | GAA | P10253 | 5/20 | 0.86 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.86 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.86 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.86 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.84 |
| ▸ | THRB | P10828 | 2/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 4/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23326605 | 0.91 | MAPT (1.00) | MAPTKMT2ALMNAMEN1GAA | |
| SCHEMBL23345498 | 0.91 | MAPT (0.86) | MAPTKMT2ALMNAMEN1GAA | |
| SCHEMBL28575183 | 0.91 | MAPT (0.86) | MAPTKMT2ALMNAMEN1GAA | |
| SCHEMBL23345457 | 0.91 | MAPT (1.00) | MAPTKMT2ALMNAMEN1GAA | |
| SCHEMBL23326607 | 0.91 | MAPT (0.86) | MAPTKMT2ALMNAMEN1GAA | |
| SCHEMBL23345463 | 0.91 | MAPT (0.86) | MAPTKMT2ALMNAMEN1GAA | |
| SCHEMBL23326606 | 0.91 | MAPT (1.00) | MAPTKMT2ALMNAMEN1GAA | |
| SCHEMBL23326610 | 0.91 | MAPT (0.86) | MAPTKMT2ALMNAMEN1GAA | |
| SCHEMBL23345496 | 0.91 | MAPT (0.82) | MAPTKMT2ALMNAMEN1GAA | |
| SCHEMBL23345479 | 0.89 | MAPT (0.82) | MAPTKMT2ALMNAMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030896-B2 | PIKfyve inhibitors | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030896-B2 | PIKfyve inhibitors | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240016810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240016810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20210139505-A1 | PIKfyve Inhibitors | Sanford Burnham Prebys Medical Discovery Institute | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030896-B2 | PIKfyve inhibitors | PIKFYVE, PIP4K2B, PIP4K2A | MAPT 3914/4885KMT2A 1410/4885LMNA 3750/4885 |
| US-20210139505-A1 | PIKfyve Inhibitors | PIKFYVE, PIP4K2B, PIP4K2A | MAPT 3914/4885KMT2A 1410/4885LMNA 3750/4885 |
| US-20240016810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS | TARDBP, PIKFYVE, FUS | MAPT 33/4885KMT2A 1078/4885LMNA 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.